Heron Therapeutics (NASDAQ:HRTX – Get Free Report) is set to release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Heron Therapeutics Price Performance
HRTX opened at $1.75 on Friday. The company has a market cap of $265.42 million, a price-to-earnings ratio of -5.47 and a beta of 1.81. The firm has a 50 day simple moving average of $1.87 and a 200 day simple moving average of $2.55. Heron Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $3.93.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 target price on shares of Heron Therapeutics in a research note on Wednesday, September 25th.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- ESG Stocks, What Investors Should Know
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 11/4 – 11/8
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.